HAYA Therapeutics reposted this
Provocative data recently appeared in JACC Journals from Hammersley et al., which finds that myocardial fibrosis is a better predictor of outcomes in cardiomyopathy than stratification by LVEF. If we can reduce fibrosis in cardiomyopathy, will better outcomes follow? #HAYAtherapeutics is developing an Antisense Oligo (#ASO) to target activated cardiac myofibroblasts which cause myocardial fibrosis. Our goal is to change the cell state and modify the disease. https://lnkd.in/e7vwxb4X
